The fourth annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in healthcare.

Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.

Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics. 

After years of convincing the medical industry about the value of its novel cancer immunotherapy, South Korea’s SillaJen may be stepping closer to its goal of commercializing the “dream cancer therapy.” The bioventure’s CEO shared his views on the product and SillaJen’s future in the first part of this exclusive interview with PharmAsia News.